First Tracks Biotherapeutics Inc (TRAX)
NASDAQ • Healthcare
Last close at October 9, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
First Tracks Biotherapeutics’ preliminary results for the second fiscal quarter of 2026, reported August 12, 2026, showed EPS of -$0.95 trailed the -$0.80 estimate by -$0.15 as the clinical-stage immunology developer continued to post losses. The company recorded GAAP operating income of roughly -$34.9 million and GAAP net income of about -$33.4 million, reflecting ongoing spending to advance its pipeline programs, including Rosnilimab, ANB033, and ANB101, through clinical development rather than commercial drug sales. Cash burn remained evident in liquidity generation as well, with negative operating cash flow of around -$31.9 million for the quarter.
About First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics Inc is a NASDAQ-listed Biotechnology company in the healthcare field that develops immunology-based treatments for autoimmune and inflammatory disorders. The company operates as a clinical-stage therapeutic developer rather than a commercial drug seller, with its work centered on discovering and advancing candidates through human testing.
Today's Snapshot
TRAX closed 0.5% lower at 31.85, against a firmer sector. Wells Fargo analysts raised their estimated share price for First Tracks Biotherapeutics to $62 from $55.
Trading Volume
Above 10d avg 763.9K
855.2K
vs S&P 500 Today
Underperforming Market
-1.09%
Updated: October 9, 2026 at 20:28 UTC
Peers & Related Assets
Get premium market insights delivered directly to your inbox.